Erratum: Overview of the RGD-based PET agents use in patients with cardiovascular diseases: A systematic review
Frontiers Production Office- Frontiers Media SA, Lausanne, Switzerland
An Erratum on
Overview of the RGD-based PET agents use in patients with cardiovascular diseases: A systematic review
by Dietz, M., Kamani, C. H., Dunet, V., Fournier, S., Rubimbura, V., Testart Dardel, N., Schaefer, A., Jreige, M., Boughdad, S., Nicod Lalonde, M., Schaefer, N., Mewton, N., Prior, J. O., and Treglia, G. (2022). Front. Med. 9:887508. doi: 10.3389/fmed.2022.887508
An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Lausanne.”
The original article has been updated.
Keywords: αvβ3 integrin, RGD, angiogenesis, positron emission tomography, cardiovascular diseases, myocardial infarction, atherosclerosis
Citation: Frontiers Production Office (2023) Erratum: Overview of the RGD-based PET agents use in patients with cardiovascular diseases: A systematic review. Front. Med. 10:1183711. doi: 10.3389/fmed.2023.1183711
Received: 10 March 2023; Accepted: 10 March 2023;
Published: 22 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org